Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.

By: Robbins LLP via GlobeNewswire

September 22, 2025 at 15:41 PM EDT

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic Inducible Urticaria (“CIndU”), and Asthma.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Jasper Therapeutics, Inc. (JSPR) Misled Investors Regarding the Commercial Prospects of its Lead Product Candidate Briquilimab

According to the complaint, defendants failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company’s products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; and (iv) accordingly, the Company’s business and/or financial prospects, as well as briquilimab’s clinical and/or commercial prospects, were overstated.

When the truth was revealed on July 7, 2025, Jasper’s stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

What Now: You may be eligible to participate in the class action against Jasper Therapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Jasper Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/